Thomas Schmittgen

Prof. Thomas Schmittgen

Department of Pharmaceutics, College of Pharmacy, Cancer Genetics Research Complex, University of Florida, 2033 Mowry Rd, P.O. Box 103633, Gainesville, FL 32610, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2017 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
DSDhruvitkumar Sutaria
Dhruvitkumar Sutaria
MBMohamed Badawi
Mohamed Badawi
MPMitch A. Phelps
Mitch A. Phelps
Thomas SchmittgenThomas Schmittgen
Thomas Schmittgen

1 December 2017 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
DSDhruvitkumar Sutaria
Dhruvitkumar Sutaria
JJJinmai Jiang
Jinmai Jiang
OEOla A. Elgamal
Ola A. Elgamal
SPSteven M. Pomeroy
Steven M. Pomeroy
MBMohamed Badawi
Mohamed Badawi
Thomas SchmittgenThomas Schmittgen
Thomas Schmittgen
Extracellular vesicles (EVs) hold great potential as novel systems for nucleic acid delivery due to their natural composition. Our goal was to load EVs with microRNA that are synthesized by the cells that produce the EVs. HEK293T cells were engineered to produce EVs expressing a lysosomal associated membrane, Lamp2a fusion protein. The gene encoding pre‐miR‐199a was inserted into an artificial intron of the Lamp2a fusion protein. The TAT peptide/HIV‐1 transactivation response (TAR) RNA interacting peptide was exploited to enhance the EV loading of the pre‐miR‐199a containing a modified TAR RNA loop. Computational modeling demonstrated a stable interaction between the modified pre‐miR‐199a loop and TAT peptide. EMSA gel shift, recombinant Dicer processing and luciferase binding assays confirmed the binding, processing and functionality of the modified pre‐miR‐199a. The TAT‐TAR interaction enhanced the loading of the miR‐199a into EVs by 65‐fold. Endogenously loaded EVs were ineffective at delivering active miR‐199a‐3p therapeutic to recipient SK‐Hep1 cells. While the low degree of miRNA loading into EVs through this approach resulted in inefficient distribution of RNA cargo into recipient cells, the TAT TAR strategy to load miRNA into EVs may be valuable in other drug delivery approaches involving miRNA mimics or other hairpin containing RNAs.

18 July 2018 in Cancers
Verified
Journal Article
Open access
PDF file
LSLisa Scarton
Lisa Scarton
SYSaunjoo Yoon
Saunjoo Yoon
SOSungho Oh
Sungho Oh
EAEdward Agyare
Edward Agyare
Jose TrevinoJose Trevino
Jose Trevino
DWDiana J Wilkie
Diana J Wilkie
We summarize the risk factors that may significantly contribute to racial disparities in pancreatic cancer, which is now the third leading cause of cancer deaths and projected to be second around 2030 in 12 years. For decades, the incidence rate of pancreatic cancer among Blacks has been 30% to 70% higher than other racial groups in the United States and the 5-year survival rate is approximately 5%. Diabetes and obesity have been identified as potentially predisposing factors to pancreatic cancer and both are more common among Blacks. Smoking continues to be one of the most important risk factors for pancreatic cancer and smoking rates are higher among Blacks compared to other racial groups. The overall risk of pancreatic cancer due to changes in DNA is thought to be the same for most racial groups; however, DNA methylation levels have been observed to be significantly different between Blacks and Whites. This finding may underlie the racial disparities in pancreatic cancer. Identification and prevention of these factors may be effective strategies to reduce the high incidence and mortality rates for pancreatic cancer among Blacks.

23 June 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
JJJinmai Jiang
Jinmai Jiang
AAAna Clara P. Azevedo-Pouly
Ana Clara P. Azevedo-Pouly
RRRoxana S. Redis
Roxana S. Redis
ELEun Joo Lee
Eun Joo Lee
YGYuriy Gusev
Yuriy Gusev
Thomas SchmittgenThomas Schmittgen
Thomas Schmittgen
Globally increased ultraconserved noncoding RNA expression in pancreatic adenocarcinoma

1 June 2017 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
JKJihye Kim
Jihye Kim
JJJinmai Jiang
Jinmai Jiang
MBMohamed Badawi
Mohamed Badawi
Thomas SchmittgenThomas Schmittgen
Thomas Schmittgen

1 April 2019 in Cancer Research
Verified
Journal Article
Open access
PDF file
Thomas SchmittgenThomas Schmittgen
Thomas Schmittgen
Both natural killer (NK) cells and exosomes released from these cells induce tumor cell cytotoxicity by way of the cell killing proteins perforin and granzyme. TGFβ1 protein in the tumor microenvironment generates an immune escape mechanism rendering NK cells inactive. The tumor-suppressive miR-186 that is downregulated in neuroblastoma and in TGFβ-treated NK cells represses oncogenic proteins in neuroblastoma (MYCN and AURKA) and components of the TGFβ pathway. Restoration of miR-186 levels in neuroblastoma through NK cell–derived exosomes or by nanoparticle delivery reduces tumor burden, promotes survival, and restores the cell-killing abilities of NK cells, demonstrating the therapeutic potential of tumor-suppressive miRNAs in neuroblastoma. See related article by Neviani and colleagues; Cancer Res 79(6):1151–64